Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain

Kristen M. Ahlschwede; Geoffry L. Curran; Jens T. Rosenberg; Samuel C. Grant; Gobinda Sarkar; Robert B. Jenkins; Subramanian Ramakrishnan; Joseph F. Poduslo; Karunya K. Kandimalla

doi:10.1016/j.nano.2018.09.010

Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain

Kristen M. Ahlschwede, Geoffry L. Curran, Jens T. Rosenberg, Samuel C. Grant, Gobinda Sarkar, Robert B. Jenkins, Subramanian Ramakrishnan, Joseph F. Poduslo, Karunya K. Kandimalla

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Accumulation of amyloid beta (Aβ) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood–brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAβ40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.

Original language	English (US)
Pages (from-to)	258-266
Number of pages	9
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	16
DOIs	https://doi.org/10.1016/j.nano.2018.09.010
State	Published - Feb 2019

Keywords

Alzheimer's disease (AD)
BBB permeating peptide
Cerebrovascular amyloid
Magnetic resonance imaging (MRI)
Targeted nanoparticles

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
General Materials Science
Pharmaceutical Science

Access to Document

10.1016/j.nano.2018.09.010

Cite this

Ahlschwede, K. M., Curran, G. L., Rosenberg, J. T., Grant, S. C., Sarkar, G., Jenkins, R. B., Ramakrishnan, S., Poduslo, J. F., & Kandimalla, K. K. (2019). Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine: Nanotechnology, Biology, and Medicine, 16, 258-266. https://doi.org/10.1016/j.nano.2018.09.010

@article{a94fd4a85ab949b0b24b25e16b121d6c,

title = "Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain",

abstract = "Accumulation of amyloid beta (Aβ) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood–brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAβ40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.",

keywords = "Alzheimer's disease (AD), BBB permeating peptide, Cerebrovascular amyloid, Magnetic resonance imaging (MRI), Targeted nanoparticles",

author = "Ahlschwede, {Kristen M.} and Curran, {Geoffry L.} and Rosenberg, {Jens T.} and Grant, {Samuel C.} and Gobinda Sarkar and Jenkins, {Robert B.} and Subramanian Ramakrishnan and Poduslo, {Joseph F.} and Kandimalla, {Karunya K.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = feb,

doi = "10.1016/j.nano.2018.09.010",

language = "English (US)",

volume = "16",

pages = "258--266",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain

AU - Ahlschwede, Kristen M.

AU - Curran, Geoffry L.

AU - Rosenberg, Jens T.

AU - Grant, Samuel C.

AU - Sarkar, Gobinda

AU - Jenkins, Robert B.

AU - Ramakrishnan, Subramanian

AU - Poduslo, Joseph F.

AU - Kandimalla, Karunya K.

PY - 2019/2

Y1 - 2019/2

N2 - Accumulation of amyloid beta (Aβ) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood–brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAβ40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.

AB - Accumulation of amyloid beta (Aβ) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood–brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAβ40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.

KW - Alzheimer's disease (AD)

KW - BBB permeating peptide

KW - Cerebrovascular amyloid

KW - Magnetic resonance imaging (MRI)

KW - Targeted nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85058220814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058220814&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.09.010

DO - 10.1016/j.nano.2018.09.010

M3 - Article

C2 - 30300748

AN - SCOPUS:85058220814

SN - 1549-9634

VL - 16

SP - 258

EP - 266

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

ER -

Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this